HER2 Overexpression as a Predictive Marker in a Randomized Trial Comparing Adjuvant Cyclophosphamide/Methotrexate/5-Fluorouracil with Epirubicin in Patients with Stage I/II Breast Cancer: Long-Term Results
Mariantonietta Colozza(Azienda Ospedaliera di Perugia), Maurizio Tonato, Bruno Mazzocchi(Ospedale Misericordia - Grosseto), E Bucciarelli(University of Perugia), Stefania Gori(Ospedale Sacro Cuore Don Calabria), Anna Maria Mosconi(Azienda Ospedaliera di Perugia), Roberta Cherubini(Azienda Ospedaliera di Perugia), Giancarlo Bisagni, Alberto Rosa Bian, Antonio Frassoldati(Italian Oncology Group of Clinical Research), Zhasmina Mihailova(Azienda Ospedaliera di Perugia), Antonio Cavaliere(University of Perugia), Verena De Angelis(University of Perugia), Angelo Sidoni(University of Perugia), Carmelina Rodinò(Guglielmo da Saliceto Hospital)
Cited by 19
Related Papers
Preoperative Chemotherapy Plus Trastuzumab, Lapatinib, or Both in Human Epidermal Growth Factor Receptor 2–Positive Operable Breast Cancer: Results of the Randomized Phase II CHER-LOB Study
|Journal of Clinical Oncology|2012|368
Zoledronic acid (zoledronate) for postmenopausal women with early breast cancer receiving adjuvant letrozole (ZO-FAST study): final 60-month results
|Annals of Oncology|2012|339
CEREBEL (EGF111438): A Phase III, Randomized, Open-Label Study of Lapatinib Plus Capecitabine Versus Trastuzumab Plus Capecitabine in Patients With Human Epidermal Growth Factor Receptor 2–Positive Metastatic Breast Cancer
|Journal of Clinical Oncology|2015|253
Adipose-Derived Mesenchymal Stem Cells as Stable Source of Tumor Necrosis Factor–Related Apoptosis-Inducing Ligand Delivery for Cancer Therapy
|Cancer Research|2010|244
Activity of gemcitabine in patients with non-small cell lung cancer: A multicentre, extended phase II study
|European Journal of Cancer|1996|242